New guidelines for treating methicillin-resistant S. aureus (MRSA) will change treatment of community-acquired skin infections

New guidelines for treating methicillin-resistant S. aureus (MRSA) will change treatment of community-acquired skin infections.

A beta-lactam (cephalexin, etc) USED to cover both purulent skin infections due to staph and cellulitis due to strep.

But now many purulent skin infections are due to community-acquired methicillin-resistant Staph aureus (CA-MRSA) and therefore are resistant to beta-lactams.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote